Complimentary access to the JTO and a 25% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 20.121, JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports. JTO CRR is indexed in PubMed Central.
JTO Clinical and Research Reports: Editor-in-Chief Applications Invited
The International Association for the Study of Lung Cancer (IASLC) invites applications for the position of Editor-in-Chief for JTO Clinical and Research Reports (JTO CRR). Dr. Alex A. Adjei will step down as Editor-in-Chief of JTO CRR in October, 2022. Through a global search, IASLC is seeking to appoint his successor for a 5-year term, anticipated to begin in November, 2022. JTO CRR is the official open access journal of the IASLC. It aims to complement the Journal of Thoracic Oncology (JTO) by offering authors a gold open access publication option and publishing the following article types in particular: Phase I trials, well-performed single-arm phase II trials, subset analyses of published trials, impactful retrospective Studies, database analysis, large institutional series, high-quality case reports, region-specific clinical trials, subspecialty thoracic oncology studies, and selected high-quality meeting reports. Learn more about the position and how to apply.
JTO by the Numbers
Recent journal articles
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
EGFR-mutated pulmonary choriocarcinoma combined with adenocarcinoma
Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant non-small cell lung cancer
One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Lung Cancer Patients (Cancer-VTE Subanalysis)
Severe Radiation-induced Lymphopenia Attenuates the Benefit of Durvalumab after Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer
A real-world analysis of immune checkpoint inhibitor-based therapy after osimertinib treatment in EGFR-mutant non-small cell lung cancer patients
Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: a post hoc efficacy analysis of KEYNOTE-189
Brief Report.A high percentage of NSCLC with germline CHEK2 mutation harbor actionable driver alterations: Survey of a cancer genomic database and review of literature
Discover the JTO
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.